{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:10:11Z","timestamp":1791861011183,"version":"4.3.4"},"reference-count":45,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Muscle-invasive bladder cancer (MIBC) represents a highly aggressive malignancy associated with significant morbidity and mortality. The current standard treatment, which includes radical cystectomy and platinum-based chemotherapy, is burdened by high toxicity and a substantial risk of relapse. For this reason, over the past decade, novel therapeutic strategies involving immune checkpoint inhibitors (ICIs), antibody\u2013drug conjugates (ADCs), and targeted therapies have been investigated. This review aims to summarize current clinical evidence and ongoing trials evaluating these approaches in the perioperative setting. Methods: A systematic search was conducted using PubMed, EMBASE, and Cochrane databases, along with abstracts from major oncology conferences (ASCO, ESMO, SGO). Clinical trials assessing ICIs, ADCs, and targeted therapies, either alone or in combination with each other or with chemotherapy, in MIBC, were included. Results: Several early-phase and phase III trials have investigated the perioperative management of MIBC. Various studies evaluated the addition of ICIs to standard chemotherapy, demonstrating promising results in terms of pathological complete response. In parallel, the encouraging outcomes with ICIs and ADCs alone in the neoadjuvant or adjuvant setting paved the way for their combination in integrated strategies. Biomarker-driven approaches, based on circulating tumor DNA and specific genomic alterations, are being actively explored to improve patient selection and personalize treatment. Conclusions: ICIs, ADCs, and targeted therapies are reshaping the therapeutic landscape of MIBC. While early results are promising, further data and biomarker validation are essential to establish their definitive role and guide clinical decision-making in the perioperative setting.<\/jats:p>","DOI":"10.3390\/cancers17244017","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:41:23Z","timestamp":1765968083000},"page":"4017","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7109-2429","authenticated-orcid":false,"given":"Antonio","family":"Cigliola","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3158","authenticated-orcid":false,"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9294-169X","authenticated-orcid":false,"given":"Doga","family":"Dengur","sequence":"additional","affiliation":[{"name":"Lewisham and Greewich Trust, London SE13 6LH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tateo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1776","authenticated-orcid":false,"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Piacentini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Inguglia","sequence":"additional","affiliation":[{"name":"UOC Oncologia ARNAS Civico Benfratelli di Cristina, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-1419","authenticated-orcid":false,"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[{"name":"UOC Oncologia ARNAS Civico Benfratelli di Cristina, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, Screening, and Prevention of Bladder Cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data","volume":"48","author":"Vale","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"Bladder Cancer, Version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials","volume":"81","author":"Burdett","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1038\/s41467-024-48480-1","article-title":"Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer","volume":"15","author":"Beckabir","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/JCO.2020.38.15_suppl.5047","article-title":"Phase Ib\/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188","volume":"38","author":"Hoimes","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial","volume":"40","author":"Funt","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e012045","DOI":"10.1136\/jitc-2025-012045","article-title":"Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): A phase 2 multicenter clinical trial","volume":"13","author":"Blanc","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat. Med."},{"key":"ref_19","unstructured":"Necchi, A. (2024, January 19\u201321). Retifanlimab Monotherapy as Neoadjuvant Therapy for Patients with Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder: Results from the Multicenter OPTIMUS Umbrella Study. Presented at the 2024 International Bladder Cancer Network (IBCN) Annual Meeting, Bern, Switzerland."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Fukushima, H., Yoshida, S., Kijima, T., Nakamura, Y., Fukuda, S., Uehara, S., Yasuda, Y., Tanaka, H., Yokoyama, M., and Matsuoka, Y. (2021). Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti\u2013PD-1 Treatment Efficacy in Urothelial Carcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020535"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chen, H., Yang, W., Xue, X., Li, Y., Jin, Z., and Ji, Z. (2022). Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.986359"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: The NABUCCO trial","volume":"26","author":"Silina","year":"2020","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2020.38.15_suppl.5012","article-title":"DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature","volume":"38","author":"Grande","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1078-0432.CCR-24-2636","article-title":"Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial","volume":"31","author":"Valderrama","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.euo.2023.11.022","article-title":"PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy","volume":"7","author":"Grivas","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S1766","DOI":"10.1016\/j.annonc.2025.09.129","article-title":"LBA110 A blinded, exploratory phase II trial of nivolumab and the GDF-15 neutralizing antibody visugromab or placebo as neoadjuvant treatment of patients with muscle-invasive bladder cancer (MIBC): Primary results of the GDFather-NEO trial","volume":"36","author":"Necchi","year":"2025","journal-title":"Ann. Oncol. Suppl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Maiorano, B.A., Catalano, M., Maiello, E., and Roviello, G. (2023). Enfortumab vedotin in metastatic urothelial carcinoma: The solution EVentually?. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1254906"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1200\/JCO.2022.40.6_suppl.435","article-title":"Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible","volume":"40","author":"Petrylak","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2025.43.16_suppl.4591","article-title":"First survival outcomes and biomarker results of SURE-01: Neoadjuvant sacituzumab govitecan (SG) monotherapy, followed by radical cystectomy (RC), in patients with muscle-invasive urothelial bladder cancer (MIBC)","volume":"43","author":"Maiorano","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_31","first-page":"e16584","article-title":"Neoadjuvant treatment with disitamab vedotin monotherapy in patients with HER2-overexpressing muscle invasive bladder cancer (MIBC): An open-label, single-arm, phase II study","volume":"43","author":"Huang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wen, F., Lin, T., Zhang, P., and Shen, Y. (2024). RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: A multi-center phase Ib\/II study (HOPE-03). Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1233196"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma","volume":"85","author":"Powles","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Powles, T., Kann, A.G., Castellano, D., Gross-Goupil, M., Nishiyama, H., Bracarda, S., Jensen, J.B., Makaroff, L., Jiang, S., and Ku, J.H. (2025). ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2511885"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_38","first-page":"77","article-title":"The effects of stage divergence on survival after radical cystectomy for urothelial cancer","volume":"23","author":"Hollenbeck","year":"2005","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S1763","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.24.00576","article-title":"First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer","volume":"42","author":"Mercinelli","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S1203","DOI":"10.1016\/j.annonc.2023.09.1014","article-title":"2365MO Study EV-103 cohort L: Perioperative treatment w\/enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w\/muscle invasive bladder cancer (MIBC)","volume":"34","author":"Sridhar","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S1767","DOI":"10.1016\/j.annonc.2025.09.131","article-title":"LBA112 Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results","volume":"36","author":"Necchi","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis","volume":"73","author":"Christensen","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/s41591-024-02814-0","article-title":"Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: A phase 2 trial","volume":"30","author":"Galsky","year":"2024","journal-title":"Nat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/4017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:51:06Z","timestamp":1765968666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/4017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":45,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17244017"],"URL":"https:\/\/doi.org\/10.3390\/cancers17244017","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}